IBEX 35
10.729,50 -35,50 (-0,33%) Euro Stoxx 50
4.918,09 -18,48 (-0,37%) Dólar/Euro
1,0661 +0,0015 (+0,14%) Petróleo Brent
87,20 +0,09 (+0,10%) Oro
2.406,70 +8,70 (+0,36%) Bitcoin EUR
59.300,65 -275,59 (-0,46%)
Tiziana Life Sciences Ltd (TLSA)
Después del cierre:
Tiziana Life Sciences Ltd
14/15 Conduit Street
London W1S 2XJ
United Kingdom
https://www.tizianalifesciences.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 9
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Gabriele Marco Antonio Cerrone M.B.A. | Founder, Executive Chairman & Interim CEO | 444k | N/A | 1972 |
| Dr. Andrea Brancale | Scientific Founder | N/A | N/A | N/A |
| Mr. Richard Clarkson Ph.D. | Scientific Founder | N/A | N/A | N/A |
| Mr. Andrew Westwell Ph.D. | Scientific Founder | N/A | N/A | N/A |
| Ms. Keeren Shah | Chief Financial Officer | N/A | N/A | 1976 |
| Dr. Matthew W. Davis M.D., R.Ph. | COO & Chief Medical Officer | N/A | N/A | N/A |
| Dr. William A. Clementi Ph.D., Pharm.D. | Chief Development Officer | N/A | N/A | N/A |
| Dr. Napoleone Ferrara M.D. | Member of Scientific Advisory Board | N/A | N/A | 1958 |
Descripción
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.
Gobierno corporativo
El ISS Governance QualityScore de Tiziana Life Sciences Ltd, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
